Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 117 от 154

Активно (без набиране) Фаза 2/3

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Active Idiopathic Inflammatory Myopathy Myositis Dermatomyositis Polymyositis +2

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/.

Начало: 12.10.2022 Край: 01.02.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +29 argenx NCT05523167

Активно (без набиране) Фаза 3

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Obesity Overweight

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

Начало: 11.10.2022 Край: 01.10.2027 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +24 Eli Lilly and Company NCT05556512

Активно (без набиране) Фаза 3

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Breast Neoplasms

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.

Начало: 04.10.2022 Край: 01.03.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +26 Eli Lilly and Company NCT05514054

Активно (без набиране) Фаза 1

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

Non-hodgkin Lymphoma

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapsed/refractory disease with a poor prognosis. The purpose of this study is to assess the safety and tolerability of epcoritamab in pediatric participants with relapsed/refractory aggressive mature B-cell neoplasms and young adult participants with Burkitt's or Burkitt-like lymphoma/leukemia. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of relapsed/refractory aggressive mature B-cell neoplasms. Participants will receive subcutaneous (SC) of epcoritamab. Approximately 15 pediatric participants with a diagnosis of relapsed/refractory aggressive mature B-cell neoplasms and and young adult participants, ages of 18-25, with a diagnosis of Burkitt's or Burkitt-like lymphoma/leukemia will be enrolled at 50 sites globally. Participants will receive subcutaneous epcoritamab in 28-day cycles. Participants will be followed for a minimum of 3 years after enrollment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 04.10.2022 Край: 01.11.2028 Възраст: 1–25 г. Лечение

Australia, Belgium, Canada +11 Genmab NCT05206357

Активно (без набиране) Фаза 1

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Leukemia, Myeloid, Acute

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).

Начало: 04.10.2022 Край: 03.03.2027 Възраст: от 12 г. Лечение

Australia, Canada, France +5 Janssen Research & Development, LLC NCT05453903

Активно (без набиране) Фаза 2

Efficacy of VTP-300 in Chronic Hepatitis B Infection

Chronic Hepatitis B

This is an open-label study to determine the efficacy, safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV, together VTP-300, in combination with low-dose nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.

Начало: 21.09.2022 Край: 01.10.2026 Възраст: 18–65 г. Лечение

Hong Kong, Taiwan, Thailand Barinthus Biotherapeutics NCT05343481

Активно (без набиране) Фаза 2

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Sarcoma, Ewing Neoplasm Metastasis

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Начало: 20.09.2022 Край: 01.12.2026 Възраст: 1–39 г. Лечение

Australia, France, Germany +4 Eli Lilly and Company NCT05440786

Активно (без набиране) Фаза 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Follicular Lymphoma (FL)

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Начало: 20.09.2022 Край: 01.12.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Genmab NCT05409066

Активно (без набиране) Фаза 2

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderately to severely active ulcerative colitis who have had an inadequate initial response, loss of response, or intolerance to one or more approved advanced therapy.

Начало: 19.09.2022 Край: 27.03.2029 Възраст: 18–65 г. Лечение

Argentina, Australia, Belgium +29 Janssen Research & Development, LLC NCT05242484

Активно (без набиране) Фаза 2

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV Unresectable Melanoma

The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.

Начало: 19.09.2022 Край: 30.03.2026 Възраст: от 18 г. Лечение

Australia, Italy Evaxion Biotech A/S NCT05309421

Активно (без набиране) Фаза 1

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumor

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

Начало: 19.09.2022 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Czechia, France +10 Revolution Medicines, Inc. NCT05462717

Активно (без набиране) Фаза 2

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Hepatitis D, Chronic

This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy

Начало: 17.09.2022 Край: 01.08.2029 Възраст: 18–69 г. Лечение

Bulgaria, France, Germany +6 Vir Biotechnology, Inc. NCT05461170

Активно (без набиране) Фаза 2

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Systemic Lupus Erythematosus

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569\_0003 \[NCT05162586\]).

Начало: 16.09.2022 Край: 12.08.2028 Възраст: 18–76 г. Лечение

Argentina, Australia, Brazil +19 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate NCT05540327

Активно (без набиране) Фаза 3

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Начало: 15.09.2022 Край: 31.12.2027 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +20 AstraZeneca NCT05450692

Активно (без набиране) Фаза 1/2

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer MCRPC Prostate Cancer

This clinical trial will evaluate the safety of Radium-223 in combination with 177Lu-PSMA-I\&T in metastatic castration-resistant prostate cancer: Phase I/II study

Начало: 13.09.2022 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05383079

Активно (без набиране) Фаза 2

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.

Начало: 13.09.2022 Край: 01.11.2026 Възраст: 12–45 г. Лечение

Australia, Canada, United States MapLight Therapeutics NCT05081245

Активно (без набиране) Фаза 3

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

Начало: 13.09.2022 Край: 06.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Janssen Research & Development, LLC NCT05528510

Активно (без набиране) Фаза 3

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Начало: 12.09.2022 Край: 10.04.2029 Възраст: 18–130 г. Лечение

Australia, Czechia, France +4 AstraZeneca NCT05057494

Активно (без набиране) Фаза 3

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Colorectal Cancer

The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

Начало: 07.09.2022 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +12 Exelixis NCT05425940

Активно (без набиране) Фаза 1

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Ovarian Cancer

The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer. Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents Study Details: Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose. Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.

Начало: 04.09.2022 Край: 01.01.2027 Възраст: от 18 г. Лечение

Australia Anthony Joshua, FRACP NCT05156892

1 … 115 116 117 118 119 … 154